

Press Release

March 24, 2011
Gothenburg

Proposal of the Election Committee regarding members of the Board etc. for Vitrolife AB (publ)

The Election Committee of Vitrolife, which was appointed in accordance with the resolution of the Annual General Meeting on April 26, 2010, consists of:

Henrik Blomquist, representing Bure Equity AB
Johan Ståhl, representing Lannebo Fonder
Martin Lewin, representing Eccenovo AB
Patrik Tigerschiöld, Chairman of the Board

The Election Committee proposes:

- that the members of the Board shall be six in number and that the company shall have a registered public accounting firm as auditor,
- that the Board fees be SEK 770,000, of which SEK 220,000 to the Chairman of the Board and SEK 110,000 to each of the other members of the Board. The amounts include remuneration for committee work. The proposal represents an increase of the fees of ten per cent. Fees to the auditor to be paid in accordance with reasonable invoicing.
- re-election of the Board members Patrik Tigerschiöld, Madeleine Olsson-Eriksson, Fredrik Mattsson, Maris Hartmanis, Tord Lendau and Barbro Fridén. Patrik Tigerschiöld is proposed for re-elected as Chairman of the Board,
- re-election of Öhrlings PricewaterhouseCoopers, with the authorized accountant Birgitta Granquist as head auditor, as auditor,
- that a new Election Committee be set up for the Annual General Meeting of 2012. It is proposed that the Election Committee is appointed in the same way as previously, whereby the Chairman of the Board contacts the three largest registered shareholders or otherwise known owners at the end of the third quarter of 2011 and asks them to appoint one member each. The three members who are appointed and the Chairman of the Board constitute the Election Committee. The Election Committee appoints a Chairman internally.

For further information, please contact

Henrik Blomquist, Chairman of the Election Committee, tel. +46 8 614 00 20
Patrik Tigerschiöld, Chairman of the Board, tel. +46 8 614 00 20

Vitrolife is a global biotechnology/medical device Group that works with developing, manufacturing and selling advanced products and systems for the preparation, cultivation and storage of human cells, tissue and organs. The company has business activities within three product areas: Fertility, Transplantation and Stem Cell Cultivation. The Fertility product area works with nutrient solutions (media), cryopreservation products and advanced consumable instruments such as needles and pipettes, for the treatment of human infertility. The Transplantation product area works with solutions and systems to evaluate and maintain organs outside the body in order to select usable organs and keep them in optimal condition while waiting for transplantation. The Stem Cell Cultivation product area works with media and instruments to enable the use and handling of stem cells for therapeutic purposes.

Vitrolife today has approximately 220 employees and its products are sold in more than 85 markets. The company is headquartered in Gothenburg, Sweden, and there are subsidiaries in USA, Australia, France, Italy, United Kingdom and Japan. Production facilities are located in Sweden and the USA. The Vitrolife share is listed on NASDAQ OMX Stockholm, Small Cap.

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452.
Tel: +46 31 721 80 00. Fax: +46 31 721 80 90. E-mail: info@vitrolife.com. Website: www.vitrolife.com.

Vitrolife is required to publish the information in this press release in accordance with the Swedish Securities Market Act. The information was submitted for publication on Thursday March 24, 2011, at 11 a.m. CET.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.